{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:02:52Z","timestamp":1790463772669,"version":"4.1.0"},"reference-count":79,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Public Health Service","award":["R01 AI043453"],"award-info":[{"award-number":["R01 AI043453"]}]},{"name":"National Research Service Award","award":["T32 CA 60395"],"award-info":[{"award-number":["T32 CA 60395"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.antiviral.2015.09.011","type":"journal-article","created":{"date-parts":[[2015,9,26]],"date-time":"2015-09-26T02:30:24Z","timestamp":1443234624000},"page":"132-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":84,"special_numbering":"C","title":["Hepatitis B virus reverse transcriptase \u2013 Target of current antiviral therapy and future drug development"],"prefix":"10.1016","volume":"123","author":[{"given":"Daniel N.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianming","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2015.09.011_b0005","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1128\/AAC.40.2.380","article-title":"Inhibition of hepatitis B virus by a novel l-nucleoside, 2\u2032-fluoro-5-methyl-beta-l-arabinofuranosyl uracil","volume":"40","author":"Balakrishna Pai","year":"1996","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.09.011_b0010","doi-asserted-by":"crossref","first-page":"4185","DOI":"10.1002\/j.1460-2075.1988.tb03315.x","article-title":"The amino-terminal domain of the hepadnaviral P-gene encodes the terminal protein (genome-linked protein) believed to prime reverse transcription","volume":"7","author":"Bartenschlager","year":"1988","journal-title":"Embo J."},{"key":"10.1016\/j.antiviral.2015.09.011_b0015","doi-asserted-by":"crossref","first-page":"7742","DOI":"10.1128\/JVI.00482-11","article-title":"A Tyr residue in the reverse transcriptase domain can mimic the protein-priming Tyr residue in the terminal protein domain of a hepadnavirus P protein","volume":"85","author":"Beck","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0020","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.antiviral.2015.06.014","article-title":"Chronic hepatitis B: a wave of new therapies on the horizon","volume":"121","author":"Block","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0025","doi-asserted-by":"crossref","first-page":"7754","DOI":"10.1128\/JVI.00483-11","article-title":"Cryptic protein priming sites in two different domains of duck hepatitis B virus reverse transcriptase for initiating DNA synthesis in vitro","volume":"85","author":"Boregowda","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0030","doi-asserted-by":"crossref","first-page":"6522","DOI":"10.1128\/JVI.00086-12","article-title":"TP-RT domain interactions of duck hepatitis B virus reverse transcriptase in cis and in trans during protein-primed initiation of DNA synthesis in vitro","volume":"86","author":"Boregowda","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0035","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2014.05.007","article-title":"Hepatitis B virus replication is blocked by a 2-hydroxyisoquinoline-1,3(2H,4H)-dione (HID) inhibitor of the viral ribonuclease H activity","volume":"108","author":"Cai","year":"2014","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.antiviral.2015.07.006","article-title":"Treatment of chronic hepatitis B with pattern recognition receptor agonists: current status and potential for a cure","volume":"121","author":"Chang","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2015.06.012","article-title":"Modeling hepatitis B virus infection, immunopathology and therapy in mice","volume":"121","author":"Cheng","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0050","doi-asserted-by":"crossref","first-page":"3459","DOI":"10.1016\/S0960-894X(02)00747-3","article-title":"Understanding the unique mechanism of L-FMAU (clevudine) against hepatitis B virus: molecular dynamics studies","volume":"12","author":"Chong","year":"2002","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.antiviral.2015.09.011_b0055","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1128\/AAC.39.4.979","article-title":"Use of 2\u2032-fluoro-5-methyl-beta-l-arabinofuranosyluracil as a novel antiviral agent for hepatitis B virus and Epstein\u2013Barr virus","volume":"39","author":"Chu","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.09.011_b0060","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2217\/fvl.14.113","article-title":"Unveiling the roles of HBV polymerase for new antiviral strategies","volume":"10","author":"Clark","year":"2015","journal-title":"Future Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0065","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s00109-001-0308-0","article-title":"Ribavirin\u2019s antiviral mechanism of action: lethal mutagenesis?","volume":"80","author":"Crotty","year":"2002","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.antiviral.2015.09.011_b0070","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1038\/srep11854","article-title":"Comparative meta-analysis of tenofovir disoproxil fumarate versus emtricitabine and tenofovir disoproxil fumarate as treatments for patients with chronic hepatitis B","volume":"5","author":"Cui","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2015.09.011_b0075","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1128\/JVI.75.10.4771-4779.2001","article-title":"Molecular modeling and biochemical characterization reveal the mechanism of hepatitis B virus polymerase resistance to lamivudine (3TC) and emtricitabine (FTC)","volume":"75","author":"Das","year":"2001","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0080","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nsmb.2223","article-title":"HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism","volume":"19","author":"Das","year":"2012","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0085","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.antiviral.2009.10.005","article-title":"In search of a selective therapy of viral infections","volume":"85","author":"De Clercq","year":"2010","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0090","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.3390\/v2061279","article-title":"Antiviral treatment of chronic hepatitis B virus (HBV) infections","volume":"2","author":"De Clercq","year":"2010","journal-title":"Viruses"},{"issue":"1264\u20131273","key":"10.1016\/j.antiviral.2015.09.011_b0095","first-page":"e1261","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.09.011_b0100","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0092-8674(80)90443-2","article-title":"Hepatitis B virus contains protein attached to the 5\u2032 terminus of its complete DNA strand","volume":"21","author":"Gerlich","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.09.011_b0105","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.antiviral.2015.06.008","article-title":"Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2015.06.019","article-title":"Synthetic RNAi triggers and their use in chronic hepatitis B therapies with curative intent","volume":"121","author":"Gish","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0115","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/B978-0-12-405880-4.00007-X","article-title":"Chapter seven \u2013 the natural course of chronic hepatitis B virus infection and its management","author":"Hadziyannis","year":"2013"},{"key":"10.1016\/j.antiviral.2015.09.011_b0120","doi-asserted-by":"crossref","first-page":"11447","DOI":"10.1128\/JVI.74.24.11447-11455.2000","article-title":"In vitro reconstitution of a functional duck hepatitis B virus reverse transcriptase: posttranslational activation by Hsp90","volume":"74","author":"Hu","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0125","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1128\/JVI.80.5.2141-2150.2006","article-title":"Hepatitis B virus reverse transcriptase and epsilon RNA sequences required for specific interaction in vitro","volume":"80","author":"Hu","year":"2006","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0130","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0076-6879(96)75013-9","article-title":"Expression and characterization of hepadnavirus reverse transcriptases","volume":"275","author":"Hu","year":"1996","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0135","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1073\/pnas.93.3.1060","article-title":"Hsp90 is required for the activity of a hepatitis B virus reverse transcriptase","volume":"93","author":"Hu","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.antiviral.2015.09.011_b0140","doi-asserted-by":"crossref","unstructured":"Hu, J., Seeger, C., 2015. Hepadnavirus genome replication and persistence. Cold Spring Harbor Perspectives in Medicine 5.","DOI":"10.1101\/cshperspect.a021386"},{"key":"10.1016\/j.antiviral.2015.09.011_b0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/emboj\/16.1.59","article-title":"Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids","volume":"16","author":"Hu","year":"1997","journal-title":"Embo J."},{"key":"10.1016\/j.antiviral.2015.09.011_b0150","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1128\/JVI.76.1.269-279.2002","article-title":"In vitro reconstitution of functional hepadnavirus reverse transcriptase with cellular chaperone proteins","volume":"76","author":"Hu","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0155","doi-asserted-by":"crossref","first-page":"13122","DOI":"10.1128\/JVI.78.23.13122-13131.2004","article-title":"Requirement of heat shock protein 90 for human hepatitis B virus reverse transcriptase function","volume":"78","author":"Hu","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0160","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.antiviral.2013.06.007","article-title":"Beta-Thujaplicinol inhibits hepatitis B virus replication by blocking the viral ribonuclease H activity","volume":"99","author":"Hu","year":"2013","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0165","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1365-2893.2010.01281.x","article-title":"Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy","volume":"18","author":"Jang","year":"2011","journal-title":"J. Viral Hepatitis"},{"key":"10.1016\/j.antiviral.2015.09.011_b0170","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1038\/emi.2013.56","article-title":"Hepatitis B virus reverse transcriptase: diverse functions as classical and emerging targets for antiviral intervention","volume":"2","author":"Jones","year":"2013","journal-title":"Emerging Microbes Infect."},{"key":"10.1016\/j.antiviral.2015.09.011_b0175","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1128\/JVI.02786-12","article-title":"Protein-primed terminal transferase activity of hepatitis B virus polymerase","volume":"87","author":"Jones","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0180","doi-asserted-by":"crossref","first-page":"5134","DOI":"10.1128\/JVI.07137-11","article-title":"In vitro epsilon RNA-dependent protein priming activity of human hepatitis B virus polymerase","volume":"86","author":"Jones","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0185","doi-asserted-by":"crossref","first-page":"4181","DOI":"10.1128\/AAC.00599-13","article-title":"Non-competitive inhibition of hepatitis B virus reverse transcriptase protein priming and DNA synthesis by the nucleoside analog clevudine","volume":"57","author":"Jones","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.09.011_b0190","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1128\/JVI.02852-13","article-title":"Comparative analysis of hepatitis B virus polymerase sequences required for viral RNA binding, RNA packaging, and protein priming","volume":"88","author":"Jones","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0195","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.3748\/wjg.v18.i47.6943","article-title":"Long-term treatment outcomes of clevudine in antiviral-naive patients with chronic hepatitis B","volume":"18","author":"Kim","year":"2012","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0200","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1586\/14787210.4.4.549","article-title":"Clevudine: a potent inhibitor of hepatitis B virus in vitro and in vivo","volume":"4","author":"Korba","year":"2006","journal-title":"Expert Rev. Anti Infect Ther."},{"key":"10.1016\/j.antiviral.2015.09.011_b0205","doi-asserted-by":"crossref","first-page":"4494","DOI":"10.1128\/JVI.02066-09","article-title":"Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients","volume":"84","author":"Kwon","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0210","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1128\/JVI.69.7.4431-4439.1995","article-title":"Nucleotide priming and reverse transcriptase activity of hepatitis B virus polymerase expressed in insect cells","volume":"69","author":"Lanford","year":"1995","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0215","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1128\/JVI.71.4.2996-3004.1997","article-title":"Transcomplementation of nucleotide priming and reverse transcription between independently expressed TP and RT domains of the hepatitis B virus reverse transcriptase","volume":"71","author":"Lanford","year":"1997","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0220","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/hep.21166","article-title":"A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B","volume":"43","author":"Lee","year":"2006","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.09.011_b0225","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1128\/JVI.02147-07","article-title":"Inhibition of hepadnavirus reverse transcriptase-epsilon RNA interaction by porphyrin compounds","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0230","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.1128\/JVI.02760-07","article-title":"Functional and structural dynamics of hepadnavirus reverse transcriptase during protein-primed initiation of reverse transcription: effects of metal ions","volume":"82","author":"Lin","year":"2008","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8C","author":"Menendez-Arias","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1128\/JVI.45.1.165-172.1983","article-title":"Protein covalently bound to minus-strand DNA intermediates of duck hepatitis B virus","volume":"45","author":"Molnar-Kimber","year":"1983","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0245","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1128\/JVI.70.5.2764-2773.1996","article-title":"A bulged region of the hepatitis B virus RNA encapsidation signal contains the replication origin for discontinuous first-strand DNA synthesis","volume":"70","author":"Nassal","year":"1996","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0250","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3851\/IMP1541","article-title":"Evaluation of the in vitro anti-HBV activity of clevudine in combination with other nucleoside\/nucleotide inhibitors","volume":"15","author":"Niu","year":"2010","journal-title":"Antiviral Ther."},{"key":"10.1016\/j.antiviral.2015.09.011_b0255","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1053\/jhep.2001.20899","article-title":"Antiviral activity of clevudine [L-FMAU, (1-(2-fluoro-5-methyl-beta, l-arabinofuranosyl) uracil)] against woodchuck hepatitis virus replication and gene expression in chronically infected woodchucks (Marmota monax)","volume":"33","author":"Peek","year":"2001","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.09.011_b0260","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jmb.2008.10.071","article-title":"Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition","volume":"385","author":"Sarafianos","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"1360\u20131368","key":"10.1016\/j.antiviral.2015.09.011_b0265","first-page":"e1361","article-title":"Effectiveness of hepatitis B treatment in clinical practice","volume":"142","author":"Scaglione","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.09.011_b0270","series-title":"Fields Virology","first-page":"2977","article-title":"Hepadnaviruses","author":"Seeger","year":"2007"},{"key":"10.1016\/j.antiviral.2015.09.011_b0275","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1128\/AAC.42.12.3200","article-title":"In vitro inhibition of hepadnavirus polymerases by the triphosphates of BMS-200475 and lobucavir","volume":"42","author":"Seifer","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2015.09.011_b0280","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1002\/hep.22959","article-title":"Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA","volume":"49","author":"Seok","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.antiviral.2015.09.011_b0285","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0045-2068(02)00502-3","article-title":"A novel mechanism for inhibition of HIV-1 reverse transcriptase","volume":"30","author":"Skillman","year":"2002","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.antiviral.2015.09.011_b0290","doi-asserted-by":"crossref","first-page":"13354","DOI":"10.1128\/JVI.01196-07","article-title":"Chaperones activate hepadnavirus reverse transcriptase by transiently exposing a C-proximal region in the terminal protein domain that contributes to epsilon RNA binding","volume":"81","author":"Stahl","year":"2007","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0295","doi-asserted-by":"crossref","first-page":"6124","DOI":"10.1093\/nar\/gkm628","article-title":"Chaperone activation of the hepadnaviral reverse transcriptase for template RNA binding is established by the Hsp70 and stimulated by the Hsp90 system","volume":"35","author":"Stahl","year":"2007","journal-title":"Nucl. Acids Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0300","doi-asserted-by":"crossref","first-page":"8265","DOI":"10.1128\/JVI.68.12.8265-8269.1994","article-title":"Priming of duck hepatitis B virus reverse transcription in vitro: premature termination of primer DNA induced by the 5\u2032-triphosphate of fialuridine","volume":"68","author":"Staschke","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0305","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/0092-8674(82)90157-X","article-title":"Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate","volume":"29","author":"Summers","year":"1982","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.09.011_b0310","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s12072-014-9537-5","article-title":"A randomized, open-label study comparing low-dose clevudine plus adefovir combination therapy with clevudine monotherapy in naive chronic hepatitis B patients","volume":"8","author":"Tak","year":"2014","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.antiviral.2015.09.011_b0315","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.antiviral.2015.04.002","article-title":"The hepatitis B virus ribonuclease H as a drug target","volume":"118","author":"Tavis","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0320","doi-asserted-by":"crossref","first-page":"e1003125","DOI":"10.1371\/journal.ppat.1003125","article-title":"The hepatitis B virus ribonuclease H is sensitive to inhibitors of the human immunodeficiency virus ribonuclease H and integrase enzymes","volume":"9","author":"Tavis","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.antiviral.2015.09.011_b0325","doi-asserted-by":"crossref","first-page":"34218","DOI":"10.1074\/jbc.M806797200","article-title":"Delayed chain termination protects the anti-hepatitis B virus drug entecavir from excision by HIV-1 reverse transcriptase","volume":"283","author":"Tchesnokov","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.09.011_b0330","doi-asserted-by":"crossref","first-page":"5857","DOI":"10.1128\/JVI.76.12.5857-5865.2002","article-title":"Distinct requirement for two stages of protein-primed initiation of reverse transcription in hepadnaviruses","volume":"76","author":"Wang","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0335","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/0092-8674(92)90599-8","article-title":"The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis","volume":"71","author":"Wang","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2015.09.011_b0340","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1128\/JVI.67.11.6507-6512.1993","article-title":"Novel mechanism for reverse transcription in hepatitis B viruses","volume":"67","author":"Wang","year":"1993","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0345","doi-asserted-by":"crossref","first-page":"38424","DOI":"10.1074\/jbc.M406241200","article-title":"Novel mechanism of inhibition of HIV-1 reverse transcriptase by a new non-nucleoside analog, KM-1","volume":"279","author":"Wang","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.antiviral.2015.09.011_b0350","doi-asserted-by":"crossref","first-page":"10079","DOI":"10.1128\/JVI.00816-12","article-title":"Carbonyl J acid derivatives block protein priming of hepadnaviral P protein and DNA-dependent DNA synthesis activity of hepadnaviral nucleocapsids","volume":"86","author":"Wang","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0355","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1128\/JVI.68.5.2994-2999.1994","article-title":"Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription","volume":"68","author":"Weber","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.7554\/eLife.00049","article-title":"Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus","volume":"1","author":"Yan","year":"2012","journal-title":"eLife"},{"key":"10.1016\/j.antiviral.2015.09.011_b0365","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.antiviral.2015.06.002","article-title":"NTCP opens the door for hepatitis B virus infection","volume":"121","author":"Yan","year":"2015","journal-title":"Antiviral Res."},{"key":"10.1016\/j.antiviral.2015.09.011_b0370","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0006-2952(96)00049-4","article-title":"Inhibition of Epstein\u2013Barr virus replication by a novel l-nucleoside, 2\u2032-fluoro-5-methyl-beta-l-arabinofuranosyluracil","volume":"51","author":"Yao","year":"1996","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0375","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.jhep.2014.10.026","article-title":"Two-year treatment outcome of chronic hepatitis B infection treated with besifovir vs. entecavir: results from a multicentre study","volume":"62","author":"Yuen","year":"2015","journal-title":"J. Hepatol."},{"key":"10.1016\/j.antiviral.2015.09.011_b0380","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1177\/095632020901900404","article-title":"Anti-hepatitis B virus activity in vitro of combinations of tenofovir with nucleoside\/nucleotide analogues","volume":"19","author":"Zhu","year":"2009","journal-title":"Antiviral Chem. Chemother."},{"key":"10.1016\/j.antiviral.2015.09.011_b0385","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2015.06.020","article-title":"Core protein: a pleiotropic keystone in the HBV lifecycle","volume":"121","author":"Zlotnick","year":"2015","journal-title":"Antiviral Res."},{"issue":"1593\u20131608","key":"10.1016\/j.antiviral.2015.09.011_b0390","first-page":"e1591","article-title":"Hepatitis B virus resistance to nucleos(t)ide analogues","volume":"137","author":"Zoulim","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.antiviral.2015.09.011_b0395","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1128\/JVI.68.1.6-13.1994","article-title":"Reverse transcription in hepatitis B viruses is primed by a tyrosine residue of the polymerase","volume":"68","author":"Zoulim","year":"1994","journal-title":"J. Virol."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215002223?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354215002223?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,8]],"date-time":"2020-09-08T20:36:11Z","timestamp":1599597371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354215002223"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":79,"alternative-id":["S0166354215002223"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.09.011","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatitis B virus reverse transcriptase \u2013 Target of current antiviral therapy and future drug development","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2015.09.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}